CD255 antibody (PE)

Catalog No. ABIN2749121

This Mouse Monoclonal antibody specifically detects in FACS. It exhibits reactivity toward Human and has been mentioned in 6+ publications.

Quick Overview for CD255 antibody (PE) (ABIN2749121)

Target: CD255

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: PE

Application: Flow Cytometry (FACS)

Clone: CARL-1

Product Details

Purpose: Anti-Hu CD255 PE

Specificity: The mouse monoclonal antibody CARL-1 recognizes an extracellular epitope of CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to induce apoptosis weakly in many cell types.

Cross-Reactivity (Details): Human

Purification: Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Immunogen: human CD255-transfected 2PK-3 cells

Isotype: IgG3 kappa

Application Details

Application Notes: Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μL reagent / 100 μL of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Restrictions: For Research Use only

Handling

Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

References

Yoriki, Akashi, Sho, Nomi, Yamato, Hotta, Takayama, Matsumoto, Wakatsuki, Migita, Yagita, Nakajima: "Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).

Brown, Ghosh, Winkles: "Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway." in: The Journal of biological chemistry, Vol. 285, Issue 23, pp. 17432-41, (2010) (PubMed).

Hosokawa, Hosokawa, Ozaki, Nakae, Matsuo: "Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts." in: Clinical and experimental immunology, Vol. 146, Issue 3, pp. 540-9, (2006) (PubMed).

Saitoh, Nakayama, Nakano, Yagita, Yamamoto, Yamaoka: "TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation." in: The Journal of biological chemistry, Vol. 278, Issue 38, pp. 36005-12, (2003) (PubMed).

Nakayama, Ishidoh, Kojima, Harada, Kominami, Okumura, Yagita: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 1, pp. 341-8, (2002) (PubMed).

Nakayama, Kayagaki, Yamaguchi, Okumura, Yagita: "Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity." in: The Journal of experimental medicine, Vol. 192, Issue 9, pp. 1373-80, (2000) (PubMed).

Target Details

Target: CD255

Background: TNF superfamily member 12,CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.,TNFSF12, APO3L, DR3LG, TWEAK, TNLG4A

Gene ID: 8742

UniProt: O43508